文献速递膀胱癌与上尿路尿路上皮癌

帕博利珠单抗联合或不联合仑伐替尼一线治疗晚期尿路上皮癌(LEAP-011):3期随机双盲试验

Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
PubMed 文献 · Eur Urol · 2023-09-29

LEAP-011为3期随机双盲试验,入组不适合顺铂或任何铂类化疗的晚期尿路上皮癌患者,1:1随机接受帕博利珠单抗200 mg每3周静脉给药联合仑伐替尼20 mg每日口服或安慰剂。共487例患者,联合组中位无进展生存期4.5个月 vs 帕博利珠单抗组4.0个月(HR 0.90,95%CI 0.72-1.14),中位总生存期11.8个月 vs 12.9个月(HR 1.14,95%CI 0.87-1.48),作者认为该联合方案的获益-风险比并不有利。

要点

  • 仑伐替尼联合帕博利珠单抗较帕博利珠单抗联合安慰剂未提高疗效
  • 联合组中位无进展生存期4.5个月,对照组4.0个月(HR 0.90)
  • 联合组3-5级治疗相关不良事件51%,对照组27%

核心结论

  • 作者认为,在晚期尿路上皮癌一线治疗中,仑伐替尼联合帕博利珠单抗相较于帕博利珠单抗联合安慰剂的获益-风险比并不有利。

研究设计与样本

  • 3期随机双盲试验LEAP-011,入组不适合顺铂为基础治疗或任何铂类化疗的晚期尿路上皮癌患者,按1:1随机分配。
  • 2019年6月25日至2021年7月21日共487例患者被分配接受仑伐替尼联合帕博利珠单抗(n=245)或安慰剂联合帕博利珠单抗(n=242)。
  • 给药方案为帕博利珠单抗200 mg每3周静脉给药,联合仑伐替尼20 mg或安慰剂每日口服一次。
  • 双主要终点为无进展生存期和总生存期,外部数据监测委员会每3个月审查安全性与有效性数据。

主要发现

  • 从随机化至数据截止日期(2021年7月26日)的中位时间为12.8个月(四分位距6.9-19.3)。
  • 联合组中位无进展生存期为4.5个月 vs 帕博利珠单抗组4.0个月(HR 0.90,95%CI 0.72-1.14)。
  • 联合组中位总生存期为11.8个月 vs 帕博利珠单抗组12.9个月(HR 1.14,95%CI 0.87-1.48)。
  • 归因于试验治疗的3-5级不良事件在仑伐替尼联合帕博利珠单抗组为123/241例(51%),在安慰剂联合帕博利珠单抗组为66/242例(27%)。
  • 本试验基于数据监测委员会的建议提前终止,早于最初计划。

关键数值与推荐

  • 双主要终点为无进展生存期与总生存期,外部数据监测委员会每3个月审查安全性与有效性数据。
  • 帕博利珠单抗剂量为200 mg静脉给药每3周一次,仑伐替尼为20 mg口服每日一次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本试验基于数据监测委员会的建议提前终止,早于最初计划。
  • 作者认为仑伐替尼联合帕博利珠单抗一线治疗的获益-风险比并不有利。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab plus lenvatinib has shown antitumor activity and acceptable safety in patients with platinum-refractory urothelial carcinoma (UC). OBJECTIVE: To evaluate pembrolizumab plus either lenvatinib or placebo as first-line therapy for advanced UC in the phase 3 LEAP-011 study. DESIGN, SETTING, AND PARTICIPANTS: Patients with advanced UC who were ineligible for cisplatin-based therapy or any platinum-based chemotherapy were enrolled. INTERVENTION: Patients were randomly assigned (1:1) to pembrolizumab 200 mg intravenously every 3 wk plus either lenvatinib 20 mg or placebo orally once daily. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Dual primary endpoints were progression-free survival (PFS) and overall survival (OS). An external data monitoring committee (DMC) regularly reviewed safety and efficacy data every 3 mo. RESULTS AND LIMITATIONS: Between June 25, 2019 and July 21, 2021, 487 patients were allocated to receive lenvatinib plus pembrolizumab (n = 245) or placebo plus pembrolizumab (n = 242). The median time from randomization to the data cutoff date (July 26, 2021) was 12.8 mo (interquartile range, 6.9-19.3). The median PFS was 4.5 mo in the combination arm and 4.0 mo in the pembrolizumab arm (hazard ratio [HR] 0.90 [95% confidence interval {CI} 0.72-1.14]). The median OS was 11.8 mo for the combination arm and 12.9 mo for the pembrolizumab arm (HR 1.14 [95% CI 0.87-1.48]). Grade 3-5 adverse events attributed to trial treatment occurred in 123 of 241 patients (51%) treated with lenvatinib plus pembrolizumab and in 66 of 242 patients (27%) treated with placebo plus pembrolizumab. This trial was terminated earlier than initially planned based on recommendation from the DMC. CONCLUSIONS: The benefit-to-risk ratio for first-line lenvatinib plus pembrolizumab was not considered favorable versus pembrolizumab plus placebo as first-line therapy in patients with advanced UC. PATIENT SUMMARY: Lenvatinib plus pembrolizumab was not more effective than pembrolizumab plus placebo in patients with advanced urothelial carcinoma.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Matsubara N, de Wit R, Balar AV, et al. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. Eur Urol. 2023. PMID: 37778952. doi:10.1016/j.eururo.2023.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。